BR9708632A - Composto calcilìticos - Google Patents

Composto calcilìticos

Info

Publication number
BR9708632A
BR9708632A BR9708632-0A BR9708632A BR9708632A BR 9708632 A BR9708632 A BR 9708632A BR 9708632 A BR9708632 A BR 9708632A BR 9708632 A BR9708632 A BR 9708632A
Authority
BR
Brazil
Prior art keywords
compounds
calcilitic
calcilic
receptor activity
calcium receptor
Prior art date
Application number
BR9708632-0A
Other languages
English (en)
Inventor
Bradford C Van Wagenen
Eric G Del Mar
James F Callahan
Derek Sheehan
Robert M Barmores
Richard M Keenan
Nikesh R Kotecha
Mervyn Thmpson
Original Assignee
Nps Pharma Inc
Smithkline Beecham Plc
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc, Smithkline Beecham Plc, Smithkline Beecham filed Critical Nps Pharma Inc
Publication of BR9708632A publication Critical patent/BR9708632A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Abstract

Patente de Invenção: <B>''COMPOSTOS CALCILìTICOS''<D>. A presente invenção refere-se a compostos calcilíticos. "Compostos calcilíticos'' referem-se aos compostos capazes de inibir atividade receptora de cálcio. Também são descritos o uso dos compostos calcilíticos para inibir atividade receptora de cálcio e/ou encontrar um efeito benéfico em um paciente, e técnicas que podem ser usadas para obter compostos calcilíticos adicionais.
BR9708632-0A 1996-04-09 1997-04-04 Composto calcilìticos BR9708632A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62960896A 1996-04-09 1996-04-09
US3226396P 1996-12-03 1996-12-03
PCT/US1997/005558 WO1997037967A1 (en) 1996-04-09 1997-04-04 Calcilytic compounds

Publications (1)

Publication Number Publication Date
BR9708632A true BR9708632A (pt) 2000-01-18

Family

ID=26708193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708632-0A BR9708632A (pt) 1996-04-09 1997-04-04 Composto calcilìticos

Country Status (19)

Country Link
US (2) US6022894A (pt)
EP (1) EP0901459B1 (pt)
JP (1) JP2001501584A (pt)
CN (1) CN1254465C (pt)
AR (1) AR008586A1 (pt)
AT (1) ATE298739T1 (pt)
AU (1) AU726659B2 (pt)
BR (1) BR9708632A (pt)
CA (1) CA2251331C (pt)
CO (1) CO4820431A1 (pt)
DE (1) DE69733649T2 (pt)
EA (1) EA002984B1 (pt)
HK (1) HK1018899A1 (pt)
IL (1) IL126458A (pt)
NZ (1) NZ332068A (pt)
PL (1) PL191027B1 (pt)
SA (1) SA97180135B1 (pt)
SG (1) SG99290A1 (pt)
WO (1) WO1997037967A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
WO1999038500A2 (en) * 1998-01-30 1999-08-05 The Brigham And Women's Hospital, Inc. The human calcium-sensing receptor in the detection and treatment of cancer
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
MY121054A (en) * 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
ECSP003590A (es) * 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
CZ2003142A3 (cs) * 2000-07-21 2003-06-18 Smithkline Beecham Corporation Kalcilytické sloučeniny
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
DE60136187D1 (de) 2000-08-11 2008-11-27 Japan Tobacco Inc Calciumrezeptor-antagonisten
EP1383511B1 (en) * 2000-10-25 2006-10-25 SmithKline Beecham Corporation Calcilytic compounds
ATE545866T1 (de) 2002-04-12 2012-03-15 Schering Corp Liganden von g-protein-gekoppelten rezeptoren und verfahren
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
FR2847250B1 (fr) * 2002-11-15 2006-09-22 Oreal Composition, notamment cosmetique, comprenant une amine secondaire ou tertiaire
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US7105537B2 (en) * 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) * 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
NZ541188A (en) * 2003-04-23 2008-01-31 Japan Tobacco Inc calcium receptor antagonists
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
JP2007523076A (ja) * 2004-02-06 2007-08-16 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
JP4629036B2 (ja) 2004-05-28 2011-02-09 田辺三菱製薬株式会社 アリールアルキルアミン化合物及びその製法
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
WO2006116204A1 (en) * 2005-04-22 2006-11-02 Novacea, Inc. Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
CA2620469C (en) 2005-09-02 2014-04-01 Amgen Inc. Methods of modulating intestinal fluid balance
DE602006010905D1 (de) 2005-11-25 2010-01-14 Galapagos Sas Harnstoff-derivate als calcium-rezeptor-modulatoren
WO2009055631A1 (en) * 2007-10-25 2009-04-30 Smithkline Beecham Corporation Calcilytic compounds
JP5025795B2 (ja) * 2008-06-05 2012-09-12 旭化成ファーマ株式会社 スルホンアミド化合物及びその用途
EP2196461A1 (de) 2008-12-15 2010-06-16 Bayer CropScience AG 4-Amino-1,2,3-benzoxathiazin-Derivate als Pestizide
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN103601645B (zh) * 2013-11-07 2016-05-25 上海适济生物科技有限公司 1-(苯乙基氨基)丙烷-2-醇类化合物或其盐的制备方法
WO2019153216A1 (zh) * 2018-02-09 2019-08-15 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
US20230095589A1 (en) * 2019-12-05 2023-03-30 Syngenta Crop Protection Ag One step process for the preparation of phenyl ethyl amine derivatives
CN116199605A (zh) * 2023-02-27 2023-06-02 上海睿腾医药科技有限公司 一种5-氯-2-羟基-二甲基苯磺酰胺的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (pt) *
GB1058822A (en) * 1963-07-30 1967-02-15 Ici Ltd 3-amino-2-hydroxypropoxy heterocyclic derivatives
GB1129072A (en) * 1966-02-01 1968-10-02 Ici Ltd Benzofuran and indole derivatives
GB1199037A (en) * 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
ES410417A1 (es) * 1973-01-08 1976-01-01 Andreu Sa Dr Procedimiento para la obtencion de aminoalcoholes derivadosdel p-acetamidofenol.
SE388849B (sv) * 1974-02-14 1976-10-18 Haessle Ab Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan
DE2530613A1 (de) * 1974-11-01 1976-05-06 Haessle Ab Aminderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
US4067904A (en) * 1975-12-19 1978-01-10 Mead Johnson & Company Alkylsulfonylphenoxypropanolamine derivatives
JPS5936617B2 (ja) * 1976-03-05 1984-09-05 大塚製薬株式会社 カルボスチリル誘導体
CH619453A5 (pt) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
DE2830211A1 (de) * 1977-07-21 1979-02-01 Sandoz Ag Substituierte indol-derivate, ihre herstellung und verwendung
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
EP0002792A1 (en) * 1978-01-03 1979-07-11 Sandoz Ag 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
DK267779A (da) * 1978-06-27 1979-12-28 Merck & Co Inc Fr&mgangsmaade til fremstilling af n-aralkylamino-propoxycyanopyridiner
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
DE2914166A1 (de) * 1979-04-07 1980-10-23 Beiersdorf Ag Arylsubstituierte furane und verfahren zu ihrer herstellung
ES480066A1 (es) * 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE2943406A1 (de) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
DE2944222A1 (de) * 1979-11-02 1981-05-14 Basf Ag, 6700 Ludwigshafen Neue aminoderivate des 1,2-benzisothiazols
JPS568319A (en) * 1980-03-26 1981-01-28 Otsuka Pharmaceut Co Ltd Antihistamine
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
JPS5780321A (en) * 1980-11-05 1982-05-19 Otsuka Pharmaceut Co Ltd Cardiotonic agent
US4376125A (en) * 1980-11-05 1983-03-08 University Of Virginia Alumni Patents Foundation Aminobenzlpropranolol and pharmaceutical preparation thereof
EP0095454A3 (de) * 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
DE3301198A1 (de) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US4517188A (en) * 1983-05-09 1985-05-14 Mead Johnson & Company 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
AU587217B2 (en) * 1985-01-15 1989-08-10 Glaxo Group Limited Amine derivatives
GB2192394A (en) * 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
US5053514A (en) * 1988-08-10 1991-10-01 Otsuka Pharmaceutical Company, Limited Cardiotonics
DE4040186A1 (de) * 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
DE4017019A1 (de) * 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
DK0584222T3 (da) * 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
CA2173747C (en) * 1991-08-23 2006-05-23 Edward F. Nemeth Calcium receptor-active arylalkyl amines
ATE312347T1 (de) * 1991-08-23 2005-12-15 Nps Pharma Inc Screening-verfahren für kalzium-rezeptor aktive verbindungen
ATE267009T1 (de) * 1993-02-23 2004-06-15 Brigham & Womens Hospital Calciumrezeptoraktive moleküle
GB9312893D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.

Also Published As

Publication number Publication date
SA97180135B1 (ar) 2006-06-12
NZ332068A (en) 2001-03-30
EA002984B1 (ru) 2002-12-26
JP2001501584A (ja) 2001-02-06
CA2251331A1 (en) 1997-10-16
PL191027B1 (pl) 2006-03-31
SG99290A1 (en) 2003-10-27
ATE298739T1 (de) 2005-07-15
AR008586A1 (es) 2000-02-09
AU726659B2 (en) 2000-11-16
US6521667B1 (en) 2003-02-18
IL126458A (en) 2004-06-20
EP0901459B1 (en) 2005-06-29
WO1997037967A1 (en) 1997-10-16
DE69733649D1 (de) 2005-08-04
US6022894A (en) 2000-02-08
PL329314A1 (en) 1999-03-15
AU2607097A (en) 1997-10-29
IL126458A0 (en) 1999-08-17
CN1254465C (zh) 2006-05-03
EA199800913A1 (ru) 1999-06-24
CA2251331C (en) 2009-06-09
CN1221401A (zh) 1999-06-30
CO4820431A1 (es) 1999-07-28
DE69733649T2 (de) 2006-05-18
HK1018899A1 (en) 2000-01-07
EP0901459A1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
BR9708632A (pt) Composto calcilìticos
BR9805544A (pt) Uso de um composto.
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
MY132705A (en) Novel compounds with analgesic effect
BR0206985A (pt) Anticorpos modificados e métodos de uso
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
BR9607260A (pt) Utilização de aerogéis em agricultura
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
MX9308199A (es) Inhibidores de enzima.
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
PT735890E (pt) Misturas de 2&#39;,3&#39;-didesoxi-inosina e hidroxicarbamida para inibicao da disseminacao retroviral
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
BR0010220A (pt) Compostos de pirimidinona
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
IT1289581B1 (it) Miscela,composizione per la protezione delle piante contenente la miscela e suo impiego
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
ATE206916T1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
DK0736033T3 (da) Hidtil ukendte terapeutiske carbohydratblandinger, som er nyttige til afhjælpning af præmenstruelt syndrom
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE58902899D1 (de) 2&#39;,3&#39;-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE NOVIDADE ( ARTIGO 8O COMBINADO COM ARTIGO 11 DA LPI VIGENTE )

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 18080064462, APRESENTADA EM 16/10/2008, EM VIRTUDE DO DISPOSTO NOS ARTS. 219, II, DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA DEVIDO AO INDEFERIMENTO DO PEDIDO PUBLICADO NA RPI NO 1968, DE 23/09/2008.

B25E Requested change of name of applicant rejected

Owner name: NPS PHARMACEUTICALS, INC. (US) , SMITHKLINE BEECHA